Are Edibles Actually Safer Than Smoking for Your Heart? The Newest Data Says Maybe Not.

For most of the last decade, the standard line in cannabis harm reduction has been clean and reassuring. Smoking is the dangerous part. Combustion is the problem. THC itself is fine. Switch to edibles or tinctures and the cardiovascular concerns largely go away. Older adults moving away from flower toward gummies have been told some version of this by their dispensary budtender, their cannabis-friendly doctor, and every wellness article written about the subject since 2017.

The newest peer-reviewed data is starting to suggest that line was always a little too clean.

Full disclosure before going further. EdibleRank reviews and ranks state-licensed edibles. The site exists because we believe edibles are the more responsible delivery format for adults who choose to use cannabis. Writing this piece cuts against our own commercial interest. We are doing it anyway because the people most likely to be reading our reviews are exactly the people who deserve a straight answer about what the science actually says.

What the older studies established

Cannabis and cardiovascular outcomes have been associated in the medical literature for decades, but the data was always tangled with tobacco use. Most cannabis smokers also smoke or have smoked tobacco, and untangling the two effects in epidemiological data is hard. The systematic reviews from 2018 onward kept finding signals (higher rates of heart attack, stroke, arrhythmia in cannabis users) but couldn't fully separate cannabis-specific risk from confounding factors.

The February 2024 paper by Jeffers and colleagues in the Journal of the American Heart Association was the first large study to seriously address that. Working with Behavioral Risk Factor Surveillance Survey data on 434,104 US adults from 2016 to 2020, they ran the analysis adjusted for tobacco use, then re-ran it on never-tobacco-smokers as a separate cohort. Daily cannabis users had 25% higher odds of heart attack and 42% higher odds of stroke compared to non-users. Among the never-tobacco subgroup, the stroke odds ratio was even higher at 2.16. The dose-response relationship was clear: more days of use per month, higher risk.

That paper still left a comfortable out for the edibles-are-fine position. Smoking was the dominant method of consumption in the survey population, and the study didn't separate edible-only users from smokers. You could read it and tell yourself the cardiovascular signal was being driven by the people inhaling combustion products, which is what cardiologists had been saying all along.

The 2025 UCSF study that complicated things

In May 2025, Leila Mohammadi and Matthew Springer at UCSF published a study in JAMA Cardiology that did separate the two. Their study, part of the CANDIDE project (CANnabis: Does It Damage Endothelium), recruited three carefully isolated groups of healthy adults aged 18 to 50: chronic cannabis smokers (three or more sessions per week for at least a year), THC-edible-only users (three or more edibles per week for at least a year, no smoking, no tobacco, no vaping), and non-users. None of the participants used nicotine in any form. Smokers had averaged 10 years of chronic use; edible users averaged 5 years.

The primary measurement was flow-mediated dilation, a standard biomarker of endothelial function. Reduced FMD predicts later heart attack, hypertension, and stroke. Non-users in the study had a mean FMD of 10.4%. Smokers were at 6.0%. Edible-only users were at 4.6%.

Translated into the percentage-reduction language the press releases used: smokers had vascular function reduced by 42% versus non-users. Edible-only users had vascular function reduced by 56%. The edible group, in this sample, scored worse than the smokers.

The sample was small. Fifty-five participants total. That is a real limitation and anyone reading this should hold the result loosely. But it is the cleanest separation of edible-only versus smoke-only effects on vascular function that exists in human subjects, and the result was the opposite of what the cannabis industry had been telling its customers.

The mechanism finding is the part nobody is talking about

Buried in the same paper is the more interesting result. The researchers also ran lab assays on participant blood serum, dosing cultured endothelial cells with serum from smokers, edible users, and non-users to see whether the blood itself was carrying something harmful.

Smokers' serum reduced nitric oxide production in the cell cultures by 27% compared to non-user serum. Edible users' serum did not. The endothelial cells incubated in edible-user blood produced normal nitric oxide and showed no signs of damage in the lab.

This is consequential. It means the smoke is doing additional cell-level damage that the THC alone is not doing. Whatever is wrong with the edible users' arteries, it isn't being carried in their bloodstream as a toxic factor. The vascular dysfunction is real but the mechanism is different from what smokers are dealing with.

Practically, this matters because it means switching from smoking to edibles still removes one entire category of cardiovascular harm: the combustion byproducts, particulate matter, and serum-level damage to endothelial cells. That is a real benefit and not a small one. It isn't the whole benefit people thought they were getting, but it is meaningful.

The dose-response curve is where the honest answer lives

The UCSF study population was heavy chronic users. The smokers averaged a decade of three-plus sessions per week. The edible group averaged five years of three-plus edibles per week. Most of these people were consuming cannabis at meaningful doses, multiple times per week, year after year.

That is not the same population as someone taking 2.5mg of a Wyld gummy on a Friday evening twice a month. Or a 60-year-old taking 5mg of Camino Midnight Blueberry an hour before bed three nights a week for sleep. Or someone microdosing 1mg in a Mr. Moxey's Sublime mint after lunch.

The Jeffers JAHA data showed a clear dose-response: risk scaled with frequency. The Mohammadi paper does the same in its population, with worsening FMD correlating to higher edible consumption. There is no plausible reading of either dataset where casual low-dose users sit at the same risk as the heavy daily users in those studies. The cardiovascular signal is real and the dose dial is real. Both things can be true.

The honest version of the harm reduction message: total exposure matters more than delivery method. A daily 100mg edible user is taking on cardiovascular risk that a casual 5mg-twice-a-week user is not. The dose, the frequency, and the years of accumulated use are doing more of the work than the choice between smoking and eating. That is uncomfortable for an industry that has been quietly encouraging tolerance creep and 100mg-per-piece products as a normal endpoint, but the data is the data.

Where CBD ratios fit in

There is preliminary evidence that CBD blunts some of the cardiovascular activation effects of THC. Animal studies have shown CBD reducing THC-induced tachycardia and blood pressure changes. Small human studies have shown 1:1 and CBD-dominant ratios producing less heart rate elevation than THC-only products at equivalent THC doses. Endothelial-function research on CBD-containing edibles in particular is thin, and we are not going to oversell it.

The reasonable read: if you are choosing between a 10mg pure THC gummy and a 5mg THC / 10mg CBD ratio gummy, the second one is probably gentler on your cardiovascular system at equivalent THC doses. The newer wave of brands that build out balanced ratios as a default (Papa & Barkley's Releaf line, the 1:1 Camino options, several of the Wyld balanced products) are not making this claim explicitly, but the formulation choice happens to align with what the limited research suggests.

What this means for the person actually deciding

If you are switching from smoking to edibles for cardiovascular reasons, the move is still defensible. You are removing combustion byproducts and the serum-level endothelial damage that comes with them. The remaining THC-related vascular signal is real but mechanistically different and probably smaller in magnitude at moderate doses.

If you are using edibles daily at high doses (50mg, 100mg, every night) and telling yourself you have eliminated cardiovascular risk because you are not smoking, the data does not support that anymore. The vascular function reductions in the UCSF edible cohort were not subtle. Cutting frequency, cutting dose, or cycling off entirely for periods is a real harm reduction strategy that nobody in this space talks about because the industry incentives run the other direction.

If you have any cardiovascular history, family history of premature heart disease, hypertension, or you are over 50, the data argues for caution regardless of consumption method. Talk to a cardiologist who will not be weird about the cannabis question. Edibles purchased from a state-licensed dispensary with a verifiable certificate of analysis are still meaningfully safer than anything from the unregulated hemp-derived market, where dosing is unreliable and contaminant testing is often performative.

The thing the cannabis industry, including review sites like this one, has been reluctant to engage with: the "edibles as medicine, not recreation" framing requires actually treating edibles like medicine. Dose carefully. Use the lowest effective amount. Take breaks. Pay attention to your body. Notice when your tolerance is climbing and ask whether the climb is worth it. The same logic that applies to any other psychoactive compound applies here, and pretending otherwise has been the industry's quiet collective failure for ten years.

The studies referenced in this piece

Jeffers AM, Glantz S, Byers AL, Keyhani S. Association of Cannabis Use With Cardiovascular Outcomes Among US Adults. Journal of the American Heart Association, February 28, 2024. The 434,104-person BRFSS analysis.

Mohammadi L, Navabzadeh M, Jiménez-Téllez N, et al. Association of Endothelial Dysfunction With Chronic Marijuana Smoking and THC-Edible Use. JAMA Cardiology, May 28, 2025. The UCSF CANDIDE study with the FMD measurements separating smokers, edible users, and non-users.

Cannon CP. Cannabis and heart concerns: A closer look. Harvard Health Publishing, July 2025. Useful clinical synthesis aimed at older adults.

Both primary studies are open-access and worth reading directly if you have any reason to be making decisions in this area. The UCSF paper in particular is short and the mechanism discussion is the part most coverage skipped.